Good day, everyone. My name is Megan, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology Investor Call to discuss recent clinical data and the ...

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for ...

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations ...

Palbociclib, ribociclib, and abemaciclib, which are FDA-approved CDK4/6 inhibitors, constitute the standard first-line treatment for advanced hormone receptor-positive (HR +) breast cancers. Although ...

The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional $60,000,000 aggregate principal amount of Convertible Notes, solely to cover ...

GLP-1 drugs male fertility research presented at ENDO 2026 finds Ozempic-class medications do not harm male hormones and may ...

Aggressive and therapy-resistant cancers present a significant challenge to treatment and are associated with poor patients’ survival. Identifying molecular pathways and compounds that target these ...

US FDA accepts Pharming’s supplemental NDA resubmission for Joenja to treat children aged 4 to 11 years with APDS: Leiden, the Netherlands Saturday, June 6, 2026, 13:00 Hrs [IST ...

Northwestern Medicine scientists have, for the first time, described the underlying mechanisms that regulate how cells rapidly change gene expression in response to hypoxia, a key feature of many ...

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, ...

There is a complex pathological relationship between diabetes and osteoporosis, two of the most common chronic diseases worldwide.

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Itovebi (inavolisib) on May 26, ...